期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

IRESSA治疗晚期非小细胞肺癌的研究进展 被引量：2

Research on Progress of IRESSA in Advanced Non-small cell Lung Cancer
下载PDF
导出
摘要 IRESSA(ZD1839,Gefitinib)作为一种能口服的小分子EGFR酪氨酸激酶抑制剂,已在多个国家获准上市,用于治疗化疗失败的晚期非小细胞肺癌。随着IRESSA的临床广泛应用和研究的逐步深入,如何选择对IRESSA敏感的患者,充分发挥其靶向性,是近年来探索如何提高IRESSA疗效的热点。本文从IRESSA疗效与患者特征、IRESSA疗效与EGFR及其下游因子的表达水平,以及IRESSA疗效与EGFR突变三个方面,将近几年的研究进展综述如下。 IRESSA （ZD1839, Gefitinib）, an orally selective drug inhibitor of the epidermal growth factor receptor （EGFR） tyrosine kinase （TK）, have been approved in the management of patients with advanced, chemotherapy-refractory non-small cell lung cancer （NSCLC） in several countries. Recently, how to predict the reponse to IRESSA has become a focus on enhancing the clinical effect of IRESSA to NSCLC patients. In this review, we discussed recent progression in three aspects, including patients＇ characteristics and efficacy of IRESSA, the expression of EGFR or its downstream molecules and IRESSA efficacy, and the mutational status of EGFR and IRESSA efficacy.
作者 韩宇 徐建明 宋三泰
机构地区 军事医学科学院附属医院肿瘤中心
出处 《中国肿瘤临床》 CAS CSCD 北大核心 2006年第2期111-114,共4页 Chinese Journal of Clinical Oncology
关键词 IRESSA 非小细胞肺癌 预测疗效 IRESSA Non-small cell lung cancer Prediction of response
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献20

  • 1Mendelsohn J,Baselga J.Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer[J].J Clin Oncol,2003,21(14):2787～2799.
  • 2Kris MG,Natale RB,Herbst RS,et al.Efficacy of gefitinib,an inhibitor of the epidermal growth factor receptor tyrosine kinase,in symptomatic patients with non-small cell lung cancer:a randomized trial[J].J Am Med Assoc,2003,290(16):2149～2158.
  • 3Fukuoka M,Yano S,Giaccone G,et al.Multi-institutional randomized phase Ⅱ trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer[J].J Clin Oncol,2003,21(12):2237～2246.
  • 4Giaccone G,Herbst RS,Manegold C,et al.Gefitinib in combination with gemcitabine and cisplatin in advanced nonsmall-cell lung cancer:a phase Ⅲ trial-INTACT 1[J].J Clin Oncol,2004,22(5):777～784.
  • 5Herbst RS,Giaccone G,Schiller JH,et al.Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer:a phase Ⅲ trial-INTACT 2[J].J Glin Oncol,2004,22 (5):785 ～ 794.
  • 6Xu JM,Azzariti A,Colucci G,et al.The effect of gefitinib (Iressa,zd1839) in combination with oxaliplatin is schedule-dependent in colon cancer cell lines[J].Cancer Chemother Pharmacol,2003,52(6):442～ 448.
  • 7Xu JM,Paradiso A,McLeod HL,et al.Evaluation of epidermal growth factor receptor tyrosine kinase inhibitors combined with chemotherapy:Is there a need for a more rational design[J]? Eur J Cancer,2004,40(12):1807～1809.
  • 8Xu JM,Azzariti A,Severino M,et al.Characterization of sequence-dependent synergy between ZD1839 ('Iressa') and oxaliplatin[J].Biochem Pharmacol,2003,66(4):551～563.
  • 9Miller VA,Kris MG,Shah N,et al.Bronchioloalveolar pathologic subtypeand smoking history predict sensitivity to gefitinib in advanced nonsmall-cell lung cancer[J].J Clin Oncol,2004,22 (6):1103～1109.
  • 10Santoro A,Cavina R,Latteri F,et al.Activity of a specific inhibitor,gefitinib (Iressa,ZD1839),of epidermal growth factor receptor in refractory non-small-cell lung cancer[J].Arm Oncol,2004,15(1):33～37.

同被引文献12

  • 1王金万,孙燕,刘永煜,于起涛,张沂平,李凯,朱允中,周清华,侯梅,管忠震,李维廉,庄武,王东林,梁后杰,秦凤展,卢辉山,刘晓晴,孙红,张燕军,王杰军,罗素霞,杨瑞合,涂远荣,王秀问,宋恕平,周静敏,游丽芬,王竞,姚晨.重组人血管内皮抑素联合NP方案治疗晚期NSCLC随机、双盲、对照、多中心Ⅲ期临床研究[J].中国肺癌杂志,2005,8(4):283-290. 被引量：625
  • 2Siegel-Lakhai WS, Beijnen JH, ScheUens JH. Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva) and gefitinib (Iressa). Oncologist, 2005, 10: 579 - 589.
  • 3Hirsch FR, Witta S. Biomarkers for prediction of sensitivity to EGFR inhibitors in non-small cell hmg cancer. Curr Opin Oncol, 2005, 17: 118 - 122.
  • 4Bunn PA Jr, Dziadziuszko R, Varella-Garcia M, et al. Biological markers for non-small cell lung cancer patient selection for epidermal growth factor receptor tyrosine kinase inhibitor therapy. Clin Cancer Res,2006, 12: 3652 - 3656.
  • 5Cappuzzo F, Hirsch FR, Rossi E, et al. Epidennal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell hmg cancer. J Natl Cancer Inst, 2005,97 : 643 - 655.
  • 6Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science, 2004, 30.4: 1497- 1500.
  • 7Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol,2003,21:3798 - 3807.
  • 8Shigematsu H, Gazdar AF. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers, Int J Cancer, 2006, 118: 257 - 262.
  • 9Gazdar AF, Minna JD. Inhibition of EGFR signaling: all mutations are not created equal. PLoS Med,2005,2:1085- 1087.
  • 10Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome. N Engl J Med, 2005, 353: 133- 144.

引证文献2

二级引证文献8

中国肿瘤临床
2006年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部